Merck & Co., Inc. (MRK) Q2 2023 Earnings Call Transcript

Merck & Co., Inc. (NYSE:MRK) Q2 2023 Earnings Conference Call August 1, 2023 9:00 AM ET

Company Participants

Peter Dannenbaum - VP, IR
Robert Davis - Chairman & CEO
Caroline Litchfield - CFO
Dean Li - President, Merck Research Labs

Conference Call Participants

Geoff Meacham - Bank of America
Mohit Bansal - Wells Fargo
Louise Chen - Cantor Fitzgerald
Seamus Fernandez - Guggenheim
Akash Tewari - Jefferies Group
Christopher Schott - JPMorgan
Daina Graybosch - Leerink Partners
Timothy Anderson - Wolfe Research
Chris Shibutani - Goldman Sachs
Andrew Baum - Citigroup
Stephen Scala - TD Cowen

Operator

Thank you for standing by. Welcome to the Merck & Co. Q2 Sales and Earnings Conference Call. At this time, all participants are in a listen-only mode, until the question-and-answer session of today’s conference. [Operator Instructions] This call is being recorded. This call is being recorded. If you have any objections, you may disconnect at this time.

I would now like to turn the call over to Mr. Peter Dannenbaum, Vice President, Investor Relations. Sir, you may begin.

Peter Dannenbaum

Thank you, Cedric, and good morning, everyone. Welcome to Merck's second quarter 2023 conference call. Speaking on today's call will be Rob Davis, Chairman and Chief Executive Officer; Caroline Litchfield, Chief Financial Officer; and Dr. Dean Li, President of Merck Research Labs.

Before we get started, I'd like to point out a few items. You will see that we have items in our GAAP results such as acquisition-related charges, restructuring costs and certain other items. You should note that we have excluded these from our non-GAAP results and provide a reconciliation in our press release.

I would like to remind you that some of the statements that we make today may be considered forward-looking statements within the meaning of the safe harbor provision